bioRxivCell BiologyPreprint
Loss of catalytic activity and impaired proteostasis in guanosine nucleotide-depleted LRRK2
Giulia FavettaiD, Susanne HerbstiD, Anna MasatoiD, Giulia TombesiiD, Lucia IannottaiD, Ilaria BattistiiD, James E. TomkinsiD, Daniah TrabzuniiD, Nicoletta PlotegheriD, Maximiliano Gabriel GutierreziD, Giorgio ArrigoniiD, Claudia ManzoniiD, Patrick Alfryn LewisiD, Elisa GreggioiD, Susanna CogoiD
Abstract
Coding mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene represent the most common cause of familial Parkinsons disease (PD), and are frequently observed in idiopathic PD. In addition, variation around the LRRK2 locus has been shown to alter PD risk by genome-wide association studies. Disease-causing mutations cluster within the catalytic core of LRRK2 - composed of GTPase (ROC) and serine-threonine kinase domains - and lead to an increase in kinase activity, resulting in hyperphosphorylation of a subset of RAB GTPases and consequent cellular toxicity. However, the interplay between LRRK2 GTPase and kinase domains, and with the surrounding scaffold regions has remained underexplored, with implications for the prediction of on- and off-target effects associated with kinase inhibition. To address this gap, here we dissected the contributions of kinase, GTPase and scaffold domains to LRRK2 function in murine macrophages and tissues expressing endogenous levels of GTP/GDP-binding deficient Lrrk2 T1348N. Guanosine nucleotide-free Lrrk2 is devoid of both GTPase and kinase activities but maintains the scaffold shell, leading to significant reshaping of Lrrk2 interactome and engagement in novel interactions. This altered functional state leads to impaired autophagy and accumulation of enlarged lysosomes and autophagic cargo in macrophages and kidneys. Since pharmacological inhibition of LRRK2 is under clinical evaluation, our results reveal retained scaffold functions upon loss of catalytic activity that warrant careful consideration.
- organism: mouse
- assay: proteomics
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein folding & dynamics
- approach: experimental assay
- approach: wet-lab / biochemical assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The structural basis for LRRK2's activation and autoinhibition
Amalia C. Villagran Suarez, Kathryn S. Hatch, … Andrés E. Leschziner·CellPeer-reviewed·Aug 10, 2026
- Loss-of-function coding variants in the Ras of Complex Proteins/GTPase domain of Leucine Rich Repeat Kinase 2
Sarah Butterfield, Susanne Herbst, Patrick Alfryn Lewis·Protein SciencePeer-reviewed·Jun 22, 2025
- The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson's disease
Maria Kedariti, Emanuele Frattini, … Nicoletta Plotegher·npj Parkinson s DiseasePeer-reviewed·Jul 19, 2022
- Regulation between LRRK2 and PP2A signaling in cellular models of Parkinsons disease
Panagiotis S. Athanasopoulos, Anna Memou, … Arjan Kortholt·Biochemical JournalPeer-reviewed·May 14, 2026
- Dopaminergic Neurodegeneration Induced by Parkinson's Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase Activity
An Phu Tran Nguyen, Elpida Tsika, … Darren J. Moore·Proceedings of the National Academy of SciencesPeer-reviewed·Jul 6, 2020
- A revised 1.6 Å structure of the GTPase domain of the Parkinson’s disease-associated protein LRRK2 provides insights into mechanisms
C.-X. Wu, J. Liao, … Q. Q. Hoang·bioRxiv·Jun 23, 2019